(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058871 A1

(51) International Patent Classification[7]: C07D 401/06, A61K 31/4184, C07D 413/14, A61P 11/00, 31/12 // (C07D 401/06, 235:00, 213:00)

(21) International Application Number:
PCT/EP2004/053620

(22) International Filing Date:
20 December 2004 (20.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03104810.1	18 December 2003 (18.12.2003)	EP
60/567,182	30 April 2004 (30.04.2004)	US
04105312.5	26 October 2004 (26.10.2004)	EP

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BONFANTI, Jean-François** [FR/FR]; 4 bis Route Nationale, F-27430 Andé (FR). **ANDRIES, Koenraad, Jozef, Lodewijk** [BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). **FORTIN, Jérôme, Michel, Claude** [FR/FR]; 22, rue des acacias, F-27460 Igoville (FR). **MULLER, Philippe** [FR/FR]; 17 Route d'Herqueville, F-27430 Andé (FR). **DOUBLET, Frédéric, Marc, Maurice** [FR/FR]; 1646, Route de Neufchatel, F-76230 Isneauville (FR). **MEYER, Christophe** [FR/FR]; 428 rue de Gouy, F-76520 Les Authieux s/l Port St Ouen (FR). **WILLEBRORDS, Rudy, Edmond** [BE/BE]; Vaartstraat 70, B-2330 Merksplas (BE). **GEVERS, Tom, Valerius, Josepha** [BE/BE]; Burgemeester Bossaertlaan 17, B-2350 Vosselaar (BE). **TIMMERMAN, Philip, Maria, Martha, Bern** [BE/BE]; Vijversstraat 211, B-3550 Hasselt (BE).

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,*

[Continued on next page]

(54) Title: MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION



(I)

(57) Abstract: The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C_{1-10}alkanediyl; R^1 is Ar^1 or a monocyclic or bicyclic heterocycle Q is R^7, pyrrolidinyl substituted with R^7, piperidinyl substituted with R^7 or homopiperidinyl substituted with R^7; one of R^{2a} and $R^{3a}$is selected from halo, optionally mono- or polysubstituted C_{1-6}alkyl, optionally mono- or polysubstituted C_{2-6}alkenyl, nitro, hydroxy, Ar^2, $N(R^{4a}R^4)$, $N(R^{4a}R^4)$sulfonyl, $N(R^{4a}R^{4b})$carbonyl, C_{1-6}alkyloxy, Ar^2oxy, Ar^2C_{1-6}alkyloxy, carboxyl, C_{1-6}alkyloxycarbonyl, or -C(=Z)Ar^2; and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then $R^{2b}$is hydrogen, C_{1-6}alkyl or halogen and $R^{3b}$is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C_{1-6}alkyl or halogen and R^{2b} is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

WO 2005/058871 A1

HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.